Although there are few clinical trial results for anti‐LAG‐3 antibodies in lymphoma, several studies have experimentally shown the potential of LAG‐3 as a target for DLBCL treatment.30, 31. Here, LAG3 is linked to diffuse large B-cell lymphoma.